Meet PSI at ASH 2026!
Hematology sponsors are navigating increasingly complex development programs as targeted therapies, immunotherapies, and cell and gene therapies continue to evolve. These programs can place greater demands on patient access, specialized site capabilities, biomarker testing, and operational planning across global studies.
PSI CRO brings extensive hematology experience, with 14 hematology drug approvals, 4,200 hematology sites across 60 countries, and 93% on-time enrollment. Our hematology expertise spans malignant and non-malignant hematology, including hematologic cancers, hemophilia and other bleeding disorders, and complex cell and gene therapy programs.
Visit PSI at Booth #2421
Meet with the PSI team to discuss hematology enrollment strategies, global feasibility and site selection, specialized site support, and how SYNETIC™ – PSI’s agentic AI-powered site intelligence platform – and VISIONAL™ can help strengthen planning and execution for complex hematology trials.
Attending team members:
- Alex Goñi
Senior Director, Business Development - Yeonjoo Kang
Senior Director, Business Development - Adam Couture
Associate Director, Business Development - Rebbecca Perez
Senior Manager, Feasibility - Carolyn Bennett
Medical Monitor - Yuliya Sedletska
Program Manager - Juila Bortsova
Director, Project Management
Related resources:
Case Study: A global non-Hodgkin lymphoma phase 3 trial in the midst of changing SoC
Blog: The shift towards precision medicine in hematology: Five sponsor takeaways from EHA 2026
Webinar: Agentic AI in Clinical Trials: Where We Are Now and Where We Are Going
White Paper: The operational reality of agentic AI in phase 2-3 trials
